Statement of Dr. Peter Hotez, President of the Sabin Vaccine Institute and Director of its Product Development Partnership on the Group of 7 (G7) Summit, at which the leaders of Japan, the United States, the United Kingdom, Germany, Canada, Italy and France affirmed a commitment to neglected tropical diseases (NTDs).
Statements and Press Releases
WASHINGTON, D.C. — November 10, 2015 — The Sabin Vaccine Institute (Sabin) today announced that Regina Rabinovich, M.D., M.P.H., has joined its Board of Trustees.
WASHINGTON, D.C. — September 16, 2014 — The Sabin Vaccine Institute (Sabin) today announced that its product development partnership (Sabin PDP) received $2 million from the Global Health Innovative Technology Fund (GHIT Fund) to develop a new therapeutic vaccine formulation for Chagas disease. Baylor College of Medicine, Eisai Co., Ltd. (Eisai) and Aeras are partnering on this project with the Sabin PDP, based at the Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development in Houston, Texas.
On June 11, 2014, Congressman Chris Smith (R-NJ) introduced a bipartisan bill in the House of Representatives to support the control and elimination of neglected tropical diseases (NTDs) in the United States and abroad. H.R. 4847, the “End Neglected Tropical Diseases Act,” calls for the expansion of USAID’s NTD program; increased U.S. Government advocacy for NTDs among international development and financing institutions; reporting from the U.S. Department of Health and Human Services on NTDs in the United States; the creation of one or more NTD centers of excellence to increase research and development (R&D); and the establishment of a panel on intestinal worm infections, one of the most pervasive NTDs.